Jolly’s Pharmacy Management and PRO assures the public that none of their Metformin ER long acting brands have been recalled
The management of Jolly’s Pharmacy assures the public that none of their Metformin ER long acting brands have been recalled. These statements came from a press release which revealed that on October 06, 2020, the United States Food and Drug Administration (FDA) announced the recall of specific brands of EXTENDED-RELEASE (ER) metformin also known as long acting metformin due to higher than acceptable levels of N-nitroso dimethylamine (NDMA), a probable carcinogen.
The FDA announced that the recall is applied to specific lots and brands of the metformin ER and recommended that makers or manufacturers of these brands should recall their tablets from the market. Pro of Jolly’s Pharmacy Carlton Languedoc voicing the release, says Jolly’s Pharmacy has an adequate supply of non-recalled metformin which is a critical part of the treatment regimen for diabetics.
Jolly’s Pharmacy have stocked metformin for years without any concerns of impurities and reiterates that none of their formulations have been implicated in any recall.
Mr. Languedoc gave professional advice on the abrupt stopping of Metformin. He said the team is working steadfastly & is open to any questions or concerns.
Pro of Jolly’s Pharmacy, Carlton Languedoc.
Current and past news stories.